<- Go Home
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Market Cap
$102.7M
Volume
1.0M
Cash and Equivalents
$15.0M
EBITDA
-$30.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$24.6M
Profit Margin
79.23%
52 Week High
$1.86
52 Week Low
$0.64
Dividend
N/A
Price / Book Value
0.67
Price / Earnings
-2.98
Price / Tangible Book Value
0.67
Enterprise Value
$14.3M
Enterprise Value / EBITDA
-0.53
Operating Income
-$34.4M
Return on Equity
20.39%
Return on Assets
-10.64
Cash and Short Term Investments
$105.7M
Debt
$17.3M
Equity
$158.8M
Revenue
$31.1M
Unlevered FCF
-$13.1M
Sector
Life Sciences Tools and Services
Category
N/A